<DOC>
	<DOCNO>NCT00451451</DOCNO>
	<brief_summary>To determine treatment BG00012 decrease number MS relapse certain time period . Other goal study determine , time , BG00012 treatment decrease number certain type brain lesion commonly see MS patient slow time take MS get bad . Other objective study determine safety tolerability BG00012 , well effect may test evaluation use assess MS. Additionally , glatiramer acetate use compare benefit risk placebo BG00012 .</brief_summary>
	<brief_title>Efficacy Safety Study Oral BG00012 With Active Reference Relapsing-Remitting Multiple Sclerosis</brief_title>
	<detailed_description>Multiple sclerosis ( MS ) chronic disease central nervous system affect approximately 400,000 person North America 365,000 person Europe . It predominantly disease young adult , primarily woman , disease onset typically occur age 20 40 .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<mesh_term>Dimethyl Fumarate</mesh_term>
	<criteria>Unless otherwise specify , eligible participate study , candidate must meet following eligibility criterion time randomization : Key Must confirm diagnosis RRMS accord McDonald criterion # 14 Must baseline EDSS 0.0 5.0 , inclusive . Must relapsingremitting disease course . Key Other chronic disease immune system , malignancy , urologic , pulmonary , gastrointestinal disease Pregnant nursing woman Note : Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>relapse</keyword>
	<keyword>multiple sclerosis</keyword>
	<keyword>oral</keyword>
	<keyword>remit</keyword>
</DOC>